Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed/refractory multiple myeloma

Randomized clinical trials have shown ixazomib, lenalidomide and dexamethasone (IRd) to be efficacious and safe in Asian patients with relapsed/refractory multiple myeloma (RRMM); however, real-world data are limited. The APEX study was a multicenter, observational cohort study of IRd conducted at 16 sites across South Korea, Malaysia, and Thailand. Overall, 104 patients treated with IRd during 2016-2023 were enrolled; data were collected by retrospective chart review and 6-month prospective follow-up. Median age at IRd initiation was 64.0 years. The primary endpoints of median time to next treatment (TTNT) and overall response rate (ORR) were 32.1 months and 72.1%, respectively (though ORR varied across countries). The secondary endpoint of median progression-free survival was 27.7 months, while median overall survival was not reached. Median TTNT and ORR were higher in elderly patients (≥65 and/or ≥70 years) than in the overall population. Adverse events occurred in 90.4% and serious adverse events occurred in 29.8% of all patients; common Grade ≥ 3 adverse drug reactions were pneumonia (9.6%), neutropenia (7.7%), and gastroenteritis (2.9%). This study demonstrated that IRd was safe and effective in real-world practice in Asia, including for elderly patients, and the results are aligned with TOURMALINE-MM1 and other real-world studies.

Authors

Institutions

Publication Details

Journal
International Journal of Hematology
Published
2025-03-20
DOI
https://doi.org/10.1007/s12185-025-03927-z
Citations
2
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
3.54

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed/refractory multiple myeloma

Suporn Chuncharunee, Young Rok, Youngil Koh, Myung-Won Lee et al.
2 citations
International Journal of Hematology
Multiple Myeloma Research and Treatments
3.54
article

Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed/refractory multiple myeloma

Suporn Chuncharunee, Young Rok, Youngil Koh, Myung-Won Lee, Hyeon‐Seok Eom, Gilbert Wilfred, S A W Fadilah, Azlan Husin, Kihyun Kım, Ji Hyun Lee, Hyo Jung Kim, Soo Chin Ng, Ho‐Jin Shin, Sung Soo Park, Hye-won Heo, Sung Hoon Jung, Joon‐Ho Moon
article en
2 citations

Abstract

Randomized clinical trials have shown ixazomib, lenalidomide and dexamethasone (IRd) to be efficacious and safe in Asian patients with relapsed/refractory multiple myeloma (RRMM); however, real-world data are limited. The APEX study was a multicenter, observational cohort study of IRd conducted at 16 sites across South Korea, Malaysia, and Thailand. Overall, 104 patients treated with IRd during 2016-2023 were enrolled; data were collected by retrospective chart review and 6-month prospective follow-up. Median age at IRd initiation was 64.0 years. The primary endpoints of median time to next treatment (TTNT) and overall response rate (ORR) were 32.1 months and 72.1%, respectively (though ORR varied across countries). The secondary endpoint of median progression-free survival was 27.7 months, while median overall survival was not reached. Median TTNT and ORR were higher in elderly patients (≥65 and/or ≥70 years) than in the overall population. Adverse events occurred in 90.4% and serious adverse events occurred in 29.8% of all patients; common Grade ≥ 3 adverse drug reactions were pneumonia (9.6%), neutropenia (7.7%), and gastroenteritis (2.9%). This study demonstrated that IRd was safe and effective in real-world practice in Asia, including for elderly patients, and the results are aligned with TOURMALINE-MM1 and other real-world studies.

International Journal of HematologyVol. 121(5)
Universiti Sains Malaysia (MY), Hospital Kuala Lumpur (MY), Kyungpook National University Hospital (KR), Samsung Medical Center (KR), Seoul National University Hospital (KR), Korea Pharma (South Korea) (KR), Pusan National University Hospital (KR), National Cancer Center (KR), Keimyung University Dongsan Medical Center (KR), Ramathibodi Hospital (TH), Chungnam National University Hospital (KR), Subang Jaya Medical Centre (MY), Chonnam National University Hwasun Hospital (KR), Hallym University Sacred Heart Hospital (KR), The Catholic University of Korea Seoul St. Mary's Hospital (KR), Queen Elizabeth Hospital (MY), Dong-A University (KR), Keimyung University (KR), Sungkyunkwan University (KR), Catholic University of Korea (KR)
Takeda Pharmaceuticals International
Openalex Percentile: Top 9%
Multiple Myeloma Research and Treatments
3.54
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.